middle.news
Why Nathan Smith’s CEO Role Could Transform NeuroScientific’s Cell Therapy Future
9:29am on Monday 28th of July, 2025 AEST
•
Biotechnology
Read Story
Why Nathan Smith’s CEO Role Could Transform NeuroScientific’s Cell Therapy Future
9:29am on Monday 28th of July, 2025 AEST
Key Points
Nathan Smith appointed CEO with extensive cell and gene therapy background
Focus on advancing StemSmart technology for immune-mediated inflammatory disorders
Priority on treating fistulising Crohn’s disease via Special Access Scheme
Equity incentives linked to commercial milestones exceeding USD $150 million
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Neuroscientific Biopharmaceuticals (ASX:NSB)
OPEN ARTICLE